Fluoroquinolone-induced hypoglycemia in an overweight nonagenarian with acute kidney injury and not on glucose-lowering therapy

Annals of Long-Term Care

Volumn 22, Issue 4, 2014, Pages 38-43

  Bhargava, Amit ^a   Brennan, Maura ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes mellitus; Fluoroquinolones; Glucose lowering therapy; Hyperglycemia; Hypoglycemia; Kidney disease

Indexed keywords

ALBUMIN; CIPROFLOXACIN; CREATININE; ENSURE; GLUCOSE; LEVOFLOXACIN; METOPROLOL; QUINOLONE DERIVATIVE;

ACUTE KIDNEY FAILURE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ATRIAL FIBRILLATION; BODY MASS; BRAIN ISCHEMIA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DELIRIUM; DEMENTIA; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLUOROQUINOLONE INDUCED HYPOGLYCEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MALE; MUCOSAL DRYNESS; NEUROIMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; SENESCENCE; SIDE EFFECT; SYSTOLIC HEART MURMUR; UNITED STATES; URINARY TRACT INFECTION; VERY ELDERLY;

EID: 84976313551     PISSN: 15247929     EISSN: 19435010     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. US Census Bureau. 2010 Census Briefs. The older population: 2010. www.census.gov/prod/cen2010/briefs/c2010br-09.pdf. Accessed March 7, 2013.
2. Baum C, Kennedy DL, Knapp DE, Faich A, Annello C. Drug Utilization in the U.S.- 1986. Rockville, MD: Department of Health and Human Services, Food and Drug Administration; 1987.
3. Bland CM. Polypharmacy and the elderly. Presented at: 2013 American College of Physicians Georgia Chapter Scientific Meeting; October 4-6, 2013; Savannah, GA. www.acponline.org/about-acp/chapters/ga/13-bland.pdf. Accessed March 18, 2014.
4. Kaysen GA, Myers BD. The aging kidney. Clin Geriatr Med. 1985;1(1):207-222.
5. MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis. 2005;41(4):435-440.
6. Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B. Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event? South Med J. 2006;99(1):52-56.
7. US Food and Drug Administration Drug Safety Communications. FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection. www.fda.gov/downloads/Drugs/DrugSafety/UCM365078.pdf. Released August 15, 2013. Accessed March 18, 2014.
8. Center for Healthcare Research & Transformation. Antibiotic prescribing and use. www.chrt.org/publications/price-of-care/issue-brief-2011-02-antibiotic-prescrib ing-and-use. Accessed March 18, 2014.
9. Mehta A. Mechanism of action of quinolones and fluoroquinolones. http://pharmax change.info/press/2011/05/mechanism-of-action-of-quinolones-and-fluoroquino lones. Published May 10, 2011. Accessed March 18, 2014.
10. Bayer HealthCare Pharmaceuticals Inc. CIPRO® (ciprofloxacin hydrochloride) tablets. www.pdr.net/drug-summary/cipro-oral-suspension-and-tablets?druglabelid=2 273&id=203. Published 2008. Accessed March 18, 2014.
11. Pham PA, Bartlett JG. Ciprofloxacin. Johns Hopkins Medicine. www.hopkinsguides.com/hopkins/ub/view/Johns-Hopkins-ABX-Guide/540128/all/Ciprofloxacin. Updated August 28, 2012. Accessed March 8, 2013.
12. Physicians Desk Reference. Levaquin. Montvale: Thompson Reuters; 2009. www.pdr.net/drug-summary/levaquin?druglabelid=271&id=993. Accessed March 8, 2014.
13. Pham PA, Bartlett JG. Levofloxacin. Johns Hopkins Medicine. www.hopkinsguides.com/hopkins/ub/view/Johns-Hopkins-ABX-Guide/540312/all/Levofloxacin. Updated August 24, 2012. Accessed March 8, 2013.
14. Rodvold KA, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy. 2001;21(10 Pt 2):233S-252S.
15. Floxin tablets [prescribing information]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc; 2008. www.accessdata.fda.gov/drugsatfda-docs/label/2008/019735s059lbl.pdf. Accessed March 18, 2014.
16. Bartlett JG, Auwaerter PG, Pham PA. Ofloxacin. In: Johns Hopkins ABX Guide. Burlington, MA: Jones & Bartlett Publishers; 2012:573.
17. Bayer HealthCare Pharmaceuticals Inc. AVELOX® (moxifloxacin hydrochloride) tablets. www.avelox.com/html/pdf/avelox-prescribing.pdf. Published December 2008. Accessed March 8, 2014.
18. Pham PA, Bartlett JG. Moxifloxacin. Johns Hopkins Medicine. www.hopkinsguides.com/hopkins/ub/view/Johns-Hopkins-ABX-Guide/540355/all/Moxifloxacin. Updated March 14, 2011. Accessed March 8, 2014.
19. Universal Drugstore (UDS). Gemifloxacin. www.universaldrugstore.com/medications/Factive/320mg. Accessed March 10, 2014.
20. Gemifloxacin [prescribing information]. Cary, NC: Cornerstone Therapeutics Inc; 2011. http://crtx.com/docs/Factive-PI.pdf. Accessed March 18, 2014.
21. Physicians Desk Reference. Noroxin. Montvale, NJ: Thompson Reuters; 2009. www.pdr.net/full-prescribing-information/noroxin?druglabelid=368. Accessed March 18, 2014.
22. Bartlett JG, Auwaerter PG, Pham PA. Norfloxacin. In: Johns Hopkins ABX Guide. Burlington, MA: Jones & Bartlett Publishers; 2012:571.
23. Roberge RJ, Kaplan R, Frank R, Fore C. Glyburide-ciprofloxacin interaction with resistant hypoglycemia. Ann Emerg Med. 2000;36(2):160-163.
24. Jick SS, Jick H, Dean AD. A follow-up safety study of ciprofloxacin users. Pharmacotherapy. 1993;13(5):461-464.
25. Akpunonu B, Michaelis J, Uy CN, et al. Multicenter, postmarketing assessment of levofloxacin in the treatment of adults with community-acquired pneumonia. Clin Infect Dis. 2004;38(suppl 1):S5-S15.
26. Wang S, Rizvi AA. Levofloxacin-induced hypoglycemia in a nondiabetic patient. Am J Med Sci. 2006;331(6):334-335.
27. Mohr JF, McKinnon PS, Peymann PJ, Kenton I, Septimus E, Okhuysen PC. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy. 2005;25(10):1303-1309.
28. US Food and Drug Administration. Notices: determination that Tequin (gatifloxacin) was withdrawn from sale for reasons of safety or effectiveness. Federal Register. 2008;73(175):52357-52358. www.gpo.gov/fdsys/pkg/FR-2008-09-09/pdf/E8-20938.pdf. Accessed March 18, 2014.
29. Frothingham R. Gatifloxacin associated with a 56-fold higher rate of glucose homeostasis abnormalities than comparator quinolones in the FDA spontaneous reporting database. Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC. Abstract A-1092.
30. Gavin JR III, Kubin R, Choudhri S, et al. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies. Drug Saf. 2004;27(9):671-686.
31. Mandavia DR, Virpariya MM, Patel TK, Tripathi CB. Moxifloxacin-induced hypoglycemia in a non-diabetic patient. Curr Drug Saf. 2012;7(2):183-185.
32. ClinicalTrials.gov. Finafloxacin for the treatment of cUTI and/or acute pyelonephritis. www.clinicaltrials.gov/ct2/show/NCT01928433?term=finafloxacin&ra nk=2. Accessed March 18, 2014.
33. Patel H, Andresen A, Vente A, et al. Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers. Antimicrob Agents Chemother. 2011;55(9):4386-4393.
34. Saraya A, Yokokura M, Gonoi T, Seino S. Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+channels. Eur J Pharmacol. 2004;497(1): 111-117.
35. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med. 2006;354(13):1352-1361.
36. Friedrich LV, Dougherty R. Fatal hypoglycemia associated with levofloxacin. Pharmacotherapy. 2004;24(12):1807-1812.
37. Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 2004;57(2):121-126.
38. Cooper JW. Probable adverse drug reactions in a rural geriatric nursing home population: a four-year study. J Am Geriatr Soc. 1996;44(2):194-197.
39. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038-2047.
40. Snyder JJ, Foley RN, Collins AJ. Prevalence of chronic kidney disease in the United States: a sensitivity analysis using the National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2009;53(2):218-228.
41. Bowling CB, Sharma P, Fox CS, O'Hare AM, Muntner P. Prevalence of reduced estimated glomerular filtration rate among the oldest old from 1988-1994 through 2005-2010. JAMA. 2013;310(12):1284-1286.
42. Cooper JW. Renal function assessment in nursing home patients. A prospective 6 month study in 282 patients. J Geriatr Drug Ther. 1991;5(3):59-72.